PMGC Holdings Inc.

ELAB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2023 FY2022
Revenue $590.1K $1.7M $766.3K
Cost of Revenue $404.8K $1.7M $319.0K
Gross Profit $185.3K $1.1M $447.3K
Gross Margin 31.4% 66.2% 58.4%
Operating Expenses
Research & Development $147.0K $7.4K $228.7K
SG&A Expense $2.2M $347.7K $1.0M
Operating Income $-7.6M $-3.2M —
Operating Margin -1,295.8% -186.2% —
Interest Expense $103.3K $19.5K $2.6K
Pretax Income $-7.7M — —
Income Tax Expense $31.0K — —
Net Income $-7.7M $-4.3M $-1.8M
Net Margin -1,313.0% -251.2% -234.9%
EPS (Basic) $-382.30 $-0.02 $-0.01
EPS (Diluted) $-382.30 $-0.02 $-0.01
Shares Outstanding (Basic) 20.4K 225.7M 200.1M
Shares Outstanding (Diluted) 20.4K 225.7M 200.1M
Dividends Per Share — — —